| 陆益金贤尹桂芝张鹏张大东.靶剂量美托洛尔对老年糖尿病并慢性心衰的疗效及安全性分析[J].,2014,14(15):2889-2892 |
| 靶剂量美托洛尔对老年糖尿病并慢性心衰的疗效及安全性分析 |
| Analysis of Efficacy and Safety of the Target Dose of Metoprolol inTreatment of Patinets with Chronic Heart Failure and Diabetes Mellitus |
| |
| DOI： |
| 中文关键词: 美托洛尔 糖尿病 慢性心衰 疗效 安全性 |
| 英文关键词: Diabetes mellitus Metoprolol Chronic heart failure Curative effect Safety |
| 基金项目: |
|
| 摘要点击次数: 554 |
| 全文下载次数: 769 |
| 中文摘要: |
| 摘要目的：探讨靶剂量美托洛尔治疗合并糖尿病的慢性心衰患者的临床疗效及安全性。方法：选取154 例老年糖尿病并慢性心
衰患者，随机分为观察组与对照组，每组77 例，观察组患者予靶剂量美托洛尔及常规治疗方案，对照组仅按常规治疗方案进行治
疗，比较两组患者治疗前后NYHA 分级、左心室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）、左心室射血分数
（LVEF）、6min 步行距离及用药安全性。结果：与治疗前相比，观察组与对照组两组患者NYHA分级、LVESD、LVEDD、LVEF、
6min 步行距离均有明显改善（P＜0.05）；与对照组患者治疗后相比，观察组患者治疗后以上指标改善更加显著（P＜0.05）。在随访
的6 个月内，观察组心脏事件发生率为3.90%，明显低于对照组的14.29%（P＜0.05）。两组患者平均空腹血糖、糖化血红蛋白不存
在显著性差异（P＞0.05），观察组血脂、血糖、肝功能、肾功能等指标均未发生显著变化。结论：靶剂量美托洛尔治疗合并糖尿病的
慢性心衰患者时，可显著改善患者的心功能及活动耐量，临床疗效好，安全性高，耐受性良好。 |
| 英文摘要: |
| ABSTRACT Objective:To explore the clinical efficacy and safety of target dose of metoprolol in the treatment of patinets with
chronic heart failure and diabetes mellitus. Methods:154 elderly patients with diabetes and chronic heart failure were randomly divided
into observation group and control group with 77 cases in each group, the patients in the observation group were treated with the target
dose of metoprolol and conventional therapy, while in the control group only received routine treatment. The indexes of NYHA
classification, end diastolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF),
6min walking distance and the medication safety of both groups were compared before and after treatment.Results: Compared with
before treatment, the indexes of NYHA grade, LVESD, LVEDD, LVEF, 6 minutes' walking distance of both groups were significantly
improved (P<0.05); Compared with patients in the control group after treatment, the above indexes improved more significantly in the
observation group (P<0.05). In the sixth month of follow-up, the incidence of cardiac events of the observation group was 3.90%,
significantly lower than that in the control group (14.29%) (P<0.05). The average fasting blood glucose, glycosylated hemoglobin of both
groups showed no significant difference (P>0.05). In the observation group, the blood glucose, blood lipid and liver function, renal
function and other indexes showed no significant change. Conclusion:The target dose of metoprolol in treatment of patinets with chronic
heart failure and diabetes mellitus, can obviously improve the cardiac function and activity in patients with tolerance, has good clinical
effect, high security and good tolerance. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
